In the ongoing genotype-stratified clinical trial (the PRECISIONS trial, NCT04300920), the effects of NAC plus standard care were evaluated in IPF patients who have the TOLLIP rs3750920 TT genotype, and the end of the study is estimated to be in 2025. The gene discussed is TOLLIP; the disease is idiopathic pulmonary fibrosis.